SCHEMBL905652

SCHEMBL905652

CC1[CH]OC(=O)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5534446 0.74
SCHEMBL6977196 0.67 USP2 (0.34)
SCHEMBL14751605 0.62
SCHEMBL432317 0.59
SCHEMBL19125529 0.59
SCHEMBL5014585 0.59
SCHEMBL431549 0.59
SCHEMBL137875 0.59
SCHEMBL13028432 0.59
SCHEMBL11298975 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6242600-B1 ANTIISCHEMIC AGENTS, ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-05 US claimed
EP-0970071-A1 2-PEPERAZINONE-1-ACETIC ACID DERIVATIVES AND THEIR USE Takeda Chemical Industries, Ltd. (JP) 2000-01-12 EP claimed
EP-0939757-A1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS Dupont Pharmaceuticals Company (US) 1999-09-08 EP claimed
WO-1998039324-A1 2-PEPERAZINONE-1-ACETIC ACID DERIVATIVES AND THEIR USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-09-11 WO claimed
WO-1997023480-A1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-07-03 WO claimed
CN-112654608-B Fused ring compound having urea structure 桑福德伯纳姆普利斯医学发现研究所 2024-05-07 CN disclosed
CN-116801884-A Combination therapy for HIV using adenosine derivatives and capsid inhibitors 腾盛博药生物科技有限公司 2023-09-22 CN disclosed
CN-102325787-B Novel antibacterial agents for the treatment of gram positive infections CUBIST PHARM INC 2014-05-28 CN disclosed
CN-101166729-B Fused heterocyclic compounds TAKAEDA CHEMICAL IND LTD 2011-08-31 CN disclosed
CN-1771231-B Calcium receptor modulating compounds and uses thereof TAKEDA CHEMICAL INDUSTRIES LTD 2011-05-25 CN disclosed
EP-2277520-A2 A pharmaceutical composition for angiotensin ii-mediated diseases Takeda Pharmaceutical Company Limited (JP) 2011-01-26 EP disclosed
US-20090239839-A1 RECEPTOR ANTAGONIST TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-24 US disclosed
US-5721263-A ANGIOTENSIN II ANTAGONIST IN COMBINATION WITH DIURETIC OR CALCIUM ANTAGONIST; TREATING HYPERTENSION TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-02-24 US disclosed
US-5719173-A ADMINISTERING A BENZIMIDAZOLE CARBOXYLATE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-02-17 US disclosed
US-5639773-A TREATING GLAUCOMA SENJU PHARMACEUTICAL CO., LTD. (JP) 1997-06-17 US disclosed
EP-0753301-A1 Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-01-15 EP disclosed
CN-1138322-A 2,3-diaminopropionic acid derivative SUMITOMO PHARMA (JP) 1996-12-18 CN disclosed
EP-0631780-A1 Use of an angiotensin II antagonist as an ocular hypotensive agent TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-01-04 EP disclosed
EP-0628313-A1 Combination of benzimidazoles having angiotensin-II antagonistic activity with dinretics or calcium antagonists TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-12-14 EP disclosed
EP-0622077-A1 Angiotensin II antagonists as a prophylactic or therapeutic drug for renal diseases TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-11-02 EP disclosed